These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38844724)

  • 1. Multivariate Analysis of Solubility Parameters for Drug-Polymer Miscibility Assessment in Preparing Raloxifene Hydrochloride Amorphous Solid Dispersions.
    Moreira GG; Taveira SF; Martins FT; Wagner KG; Marreto RN
    AAPS PharmSciTech; 2024 Jun; 25(5):127. PubMed ID: 38844724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-Stage Approach for a Systematic Screening and Development of Etravirine Amorphous Solid Dispersions by Hot-Melt Extrusion.
    Simões MF; Pereira A; Cardoso S; Cadonau S; Werner K; Pinto RMA; Simões S
    Mol Pharm; 2020 Feb; 17(2):554-568. PubMed ID: 31774685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of the suitable polymer for supercritical fluid assisted preparation of carvedilol solid dispersions.
    Djuris J; Milovanovic S; Medarevic D; Dobricic V; Dapčević A; Ibric S
    Int J Pharm; 2019 Jan; 554():190-200. PubMed ID: 30414899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-polymer miscibility, interactions, and precipitation inhibition studies for the development of amorphous solid dispersions for the poorly soluble anticancer drug flutamide.
    Trivino A; Gumireddy A; Meng F; Prasad D; Chauhan H
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1277-1291. PubMed ID: 31111732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mid-infrared spectroscopy as a polymer selection tool for formulating amorphous solid dispersions.
    Wegiel LA; Mauer LJ; Edgar KJ; Taylor LS
    J Pharm Pharmacol; 2014 Feb; 66(2):244-55. PubMed ID: 24433425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion.
    Metre S; Mukesh S; Samal SK; Chand M; Sangamwar AT
    Mol Pharm; 2018 Feb; 15(2):652-668. PubMed ID: 29287144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-Carrier Miscibility in Solid Dispersions of Glibenclamide and a Novel Approach to Enhance Its Solubility Using an Effervescent Agent.
    Pisay M; Bhaskar KV; Mehta CH; Nayak UY; Koteshwara KB; Mutalik S
    AAPS PharmSciTech; 2022 Oct; 23(8):284. PubMed ID: 36253571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Flory-Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying.
    Tian Y; Caron V; Jones DS; Healy AM; Andrews GP
    J Pharm Pharmacol; 2014 Feb; 66(2):256-74. PubMed ID: 24192445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation into Intermolecular Interactions and Phase Behavior of Binary and Ternary Amorphous Solid Dispersions of Ketoconazole.
    Sarpal K; Tower CW; Munson EJ
    Mol Pharm; 2020 Mar; 17(3):787-801. PubMed ID: 31860316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid state interaction of raloxifene HCl with different hydrophilic carriers during co-grinding and its effect on dissolution rate.
    Garg A; Singh S; Rao VU; Bindu K; Balasubramaniam J
    Drug Dev Ind Pharm; 2009 Apr; 35(4):455-70. PubMed ID: 19048425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis.
    Forster A; Hempenstall J; Tucker I; Rades T
    Int J Pharm; 2001 Sep; 226(1-2):147-61. PubMed ID: 11532578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailoring supersaturation from amorphous solid dispersions.
    Li N; Taylor LS
    J Control Release; 2018 Jun; 279():114-125. PubMed ID: 29654798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of preparation methods on solid state supersaturation of amorphous solid dispersions: a case study with itraconazole and eudragit e100.
    Janssens S; De Zeure A; Paudel A; Van Humbeeck J; Rombaut P; Van den Mooter G
    Pharm Res; 2010 May; 27(5):775-85. PubMed ID: 20195707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
    Meng F; Gala U; Chauhan H
    Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effervescence-induced amorphous solid dispersions with improved drug solubility and dissolution.
    Pisay M; Yarlagadda DL; Vullendula SKA; Bhat K; Kunnatur Balasundara K; Mutalik S
    Pharm Dev Technol; 2023 Feb; 28(2):176-189. PubMed ID: 36688412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation into the role of polymeric carriers on crystal growth within amorphous solid dispersion systems.
    Tian Y; Jones DS; Andrews GP
    Mol Pharm; 2015 Apr; 12(4):1180-92. PubMed ID: 25692314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Miscibility/stability considerations in binary solid dispersion systems composed of functional excipients towards the design of multi-component amorphous systems.
    Yoo SU; Krill SL; Wang Z; Telang C
    J Pharm Sci; 2009 Dec; 98(12):4711-23. PubMed ID: 19462469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lacidipine Amorphous Solid Dispersion Based on Hot Melt Extrusion: Good Miscibility, Enhanced Dissolution, and Favorable Stability.
    Xi L; Song H; Wang Y; Gao H; Fu Q
    AAPS PharmSciTech; 2018 Oct; 19(7):3076-3084. PubMed ID: 30094722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Navigating the Solution to Drug Formulation Problems at Research and Development Stages by Amorphous Solid Dispersion Technology.
    Tripathi D; B H MP; Sahoo J; Kumari J
    Recent Adv Drug Deliv Formul; 2024; 18(2):79-99. PubMed ID: 38062659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissolution and Solubility Enhancement of the Highly Lipophilic Drug Phenytoin via Interaction with Poly(N-isopropylacrylamide-co-vinylpyrrolidone) Excipients.
    Widanapathirana L; Tale S; Reineke TM
    Mol Pharm; 2015 Jul; 12(7):2537-43. PubMed ID: 26046484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.